Neuroimaging and CSF Biomarker RFP

    From Institute for the Study of Aging Inc. (Alzheimer's Drug Discovery Foundation)

    The mission details of the funder are not explicitly provided in the given description.

    Type of Support

    Overview

    The grant program aims to advance the development and validation of biomarkers for Alzheimer's disease and related dementias, addressing a clear clinical need. It prioritizes biomarkers that have a defined context of use, demonstrate an advantage over existing ones, and show potential for commercialization or clinical application. The focus is on: developing novel PET ligands for clinical trials, supporting innovative CSF biomarkers, validating MRI approaches in larger cohorts, and creating new measures of functional activity such as EEG. High priority areas include novel biomarkers of neuroinflammation, synaptic integrity, autophagy, and TDP-43, among others. The grant offers up to $600,000 depending on the stage and scope of research, for one year, with the possibility of additional funding, covering only direct costs.

    Eligibility

    Organization's Location
    eu amet
    Program Location
    id
    Organization Type
    Sint pariatur do
    Velit ex ullamco
    Ipsum Lorem
    Other
    • elit tempor minim
    up to 6M

    Submission

    Schedule
    Step 1: in nostrud adipisicing
    Application deadline
    Mar 16, 2025
    Step 2: eu pariatur (ea eu)
    Review Criteria

    proident elit elit quis dolore magna